bax
medic deliveri md nutrit busi remain
recoveri mode post-hurrican maria thu close watch
investor check identifi potenti driver could
contribut us iv therapi sale
would repres half estim q/q sale increas us
iv therapi expect price increas mini-bag
share recaptur syring push drive much sequenti
sale growth us iv therapi earli leas upgrad
sigma spectrum pump drive sequenti growth us infus
sale addit check suggest increas
suppli us iv market like help drive
contract opportun believ posit
md growth forecast bit conserv vs
guidanc year guidanc busi like
pharmaceut outperform recent nutrit
recoveri continu modest pace expect like
remain net-net check suggest recoveri
md larg complet deliv stabl
growth go forward rais price target
base updat ev/ebitda dcf analysi
expect iv therapi drive sequenti md sale growth
forecast ww md sale grow
larg driven higher iv therapi sale recent
us channel check point sever like driver sequenti
growth specif us iv therapi estim potenti
increment revenu low-singl digit full year
price increas least coupl million dollar sale increas
mini-bag share recaptur increment sale
new lvp larg volum parenter account win aggreg
like driver would account half
estim q/q us iv therapi sale increas
expect remain q/q increas us iv therapi sale
stem driver explicitli identifi check ou
forecast iv therapi sale increas q/q
base bax abil expand ou product suppli
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
adjust spin-off baxalta
compani data secur llc estim reuter
continu previou page
mini-bag like continu recaptur share re-launch mini-bag fall
tri recaptur market share recal post-hurrican maria suppli shortag
prompt hospit chang practic guidelin use manual syring estim lost
mini-bag sale annual result suppli issu channel
check indic less conveni manual syring offer hospit potenti meaning cost
save mini-bag like make harder revert back howev also understand
mini-bag eas nurs workload reduc potenti contamin sell
point believ focus believ take time increas sales/market effort
re-integr mini-bag practic includ educ hospit pharmaci committe
expect recoveri continu much consist bax expect
recaptur much lost share year mini-bag gener above-averag margin thu
margin accret revenu grow
expect sequenti growth iv therapi infus system us iv therapi
see q/q growth stem price increas continu mini-bag share recaptur similar
math equat identifi q/q us iv therapi revenu growth
infus system model assum sequenti revenu increas
anoth us check suggest possibl earli custom leas upgrad
although estim may somewhat aggress bax sigma spectrum version includ
commun industry-lead drug librari could attract upgrad exist
leas custom ou began roll new evo iq pump drive sustain
growth new pump placement associ dispos revenu said note
time capit placement associ revenu may variabl due equip instal
set custom
md recoveri growth acceler expect continu deliv md sale
growth ex-fx impli growth reach full year growth guidanc
note yr/yr comp get easier iv therapi infus system
yr/yr basi md sale growth conserv manag guidanc
howev off-set above-guid forecast outperform
recent estim sale growth ex-fx vs guidanc growth
channel check also indic new lvp contract often provid entri hospit
busi translat increment revenu opportun area like infus system inject
even nutrit
increas suppli us iv market may help contract earli re-direct
ou lvp suppli us help allevi perpetu market shortag understand
suppli player also improv past month believ
stabl reliabl suppli lvp us market help drive market back
toward contract volum believ leverag suppli capac extend exist
sign new contract reduc need non-contract lvp purchas tend yield
higher price vast major bax lvp sale remain contract-bas believ
well posit given divers hospit product portfolio leverag part
overal discuss hospit custom
new us iv competit unlik materi chang market near-term may
 braun announc invest expand iv fluid manufactur facil enhanc iv
distribut us channel check suggest braun histor rel modest share
us iv market estim despit suffici capac may relat braun
limit addit hospit offer rel competitor like take-away
 braun increas capac unlik materi take share addit freseniu
agreement distribut iv solut us market understand partner
full iv portfolio competit time howev iv offer creat strateg opportun
enhanc overal posit us hospit market pump
new competitor pump approv accord fda websit ivenix receiv approv lvp
infus pump earli june channel check suggest invenix infus system
competit platform lvp space intuit pump good cybersecur measur instant
commun good accuraci howev current player icu well entrench
infus market believ ivenix need partner larger player compet
effect gain market share recal plan launch new pump platform
start ultim includ lvp insulin pump pca patient-control analges
ambulatori pump new platform expect vertic modular thu allow hospit add
system minim footprint icu current market leader also indic
work new pump platform
nutrit recoveri expect remain modest pace follow hurrican maria
note recoveri take time busi pre-hurrican market opportun may
fulli recov addit competitor freseniu kabi launch triple-chamb bag parenter
nutrit may view conveni ready-to-us solut compar bax dual-
chamber bag howev understand compani sell triple-chamb bag outsid
us adopt kabi triple-chamb technolog modest sens would
pursu us approv triple-chamb bag see meaning us market opportun nutrit
sale growth ex-fx impli growth reach full year guidanc
compar estim expect growth acceler continu nearli
recoveri continu expect launch clinimix pend fda approv
repres bax first new product nutrit decad
md sale growth stabil start continu expect overal sale
growth acceler next year given headwind face continu
see transit year md busi start return pre-hurrican run rate estim
md growth start slightli bax estim market growth
compani plan global roll new pump platform long-term contract iv market
help sustain growth momentum beyond overal forecast sale
growth ex-fx oper ex-cyclo direct consist
guidanc respect expect sale growth acceler ex-fx
oper part driven normal growth iv therapi launch new pump
platform new product pharmaceut new ready-to-us short-act insulin
continu recoveri nutrit
price target
price target base equal weight ev/ebtida dcf p/e/g risk
thesi includ unexpect competit headwind could slow restructur effort signific delay new
believ deliv guidanc acceler sale growth margin expans ep
growth
baxter global medic product compani focus hospit product renal compani
report sale billion ex-fx growth
